Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
This Burst CME features an expert-led
video discussion on TL1A pathophysiology, which has led to a promising new class
of biologics for moderate-to-severe IBD with potential to transform care by
addressing both inflammatory and fibrostenotic
complications. Emerging evidence on TL1A genetic variants may also help
identify patients most likely to benefit, advancing individualized precision
medicine. This unique format is designed to accommodate the busy clinician and
provide a quick, go-to resource on the topic.
Target Audience
This educational activity is primarily directed toward
gastroenterologists, internists, primary care physicians, nurse practitioners, and physician assistants. Other
clinicians involved in the care of IBD will also be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the key role TL1A plays in the inflammatory pathophysiology of IBD
- Explain the implications of genetic polymorphisms with functional consequences on the stratification of patients with UC or CD